Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

被引：0
|
作者：
G. S. Falchook
M. Duvic
D. S. Hong
J. Wheler
A. Naing
J. Lim
R. Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)
[2] The University of Texas MD Anderson Cancer Center,Unit 455
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bortezomib; Gemcitabine; Liposomal doxorubicin; Cutaneous T-cell lymphoma; Small cell carcinoma; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1117 / 1126
页数：9
相关论文
共 50 条
  • [41] Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
    R. van der Noll
    W. M. Smit
    A. N. M. Wymenga
    D. S. Boss
    M. Grob
    A. D. R. Huitema
    H. Rosing
    M. M. Tibben
    M. Keessen
    H. Rehorst
    J. H. Beijnen
    J. H. M. Schellens
    Investigational New Drugs, 2015, 33 : 1197 - 1205
  • [42] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Brell, Joanna M.
    Krishnamurthi, Smitha S.
    Rath, Linda
    Bokar, Joseph A.
    Savvides, Panayiotis
    Gibbons, Joseph
    Cooney, Matthew M.
    Meropol, Neal J.
    Ivy, Percy
    Dowlati, Afshin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 547 - 553
  • [43] A Phase I Trial to Determine the Safety of Imatinib in Combination With Vatalanib in Patients With Advanced Malignancies
    Spigel, David
    Jones, Suzanne
    Hainsworth, John
    Infante, Jeff
    Greco, F. Anthony
    Thompson, Dana
    Doss, Habib
    Burris, Howard
    CANCER INVESTIGATION, 2011, 29 (04) : 308 - 312
  • [44] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Joanna M. Brell
    Smitha S. Krishnamurthi
    Linda Rath
    Joseph A. Bokar
    Panayiotis Savvides
    Joseph Gibbons
    Matthew M. Cooney
    Neal J. Meropol
    Percy Ivy
    Afshin Dowlati
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 547 - 553
  • [45] A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
    Yun Yen
    Kim Margolin
    James Doroshow
    Mayer Fishman
    Bonny Johnson
    Caroline Clairmont
    Dan Sullivan
    Mario Sznol
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 331 - 342
  • [46] Pegylated Liposomal Doxorubicin and Gemcitabine in Patients With Advanced Hepatocellular Carcinoma Results of a Phase 2 Study
    Lombardi, Giuseppe
    Zustovich, Fable
    Farinati, Fabio
    Cillo, Umberto
    Vitale, Alessandro
    Zanus, Giacomo
    Donach, Martin
    Farina, Miriam
    Zovato, Stefania
    Pastorelli, Davide
    CANCER, 2011, 117 (01) : 125 - 133
  • [47] Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
    Mekhail, T
    Hutson, TE
    Elson, P
    Budd, GT
    Srkalovic, G
    Olencki, T
    Peereboom, D
    Pelley, R
    Bukowski, RM
    CANCER, 2003, 97 (01) : 170 - 178
  • [48] A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
    Yen, Y
    Margolin, K
    Doroshow, J
    Fishman, M
    Johnson, B
    Clairmont, C
    Sullivan, D
    Sznol, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (04) : 331 - 342
  • [49] Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer
    D'Agostino, G
    Ferrandina, G
    Garganese, G
    Salerno, MG
    Lorusso, D
    Farnetano, MG
    Mancuso, S
    Scambia, G
    ONCOLOGY, 2002, 62 (02) : 110 - 114
  • [50] Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
    Rixe, Olivier
    Puzanov, Igor
    LoRusso, Patricia M.
    Cohen, Roger B.
    Morris, John C.
    Olowokure, Olugbenga O.
    Yin, Jian Y.
    Doroumian, Severine
    Shen, Liji
    Olszanski, Anthony J.
    ANTI-CANCER DRUGS, 2015, 26 (07) : 785 - 792
12345